Mylan NV $ 21.85 -0.29 (-1.31%)
MYL News and Headlines - Mylan NV
The investor sold out of Mylan NV (MYL). The portfolio was impacted by -1.42%.
The generic pharmaceutical manufacturer has a market cap of $11.18 billion and an enterprise value of $23.97 billion.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. The return on equity of 0.4% and return on assets of 0.15% are underperforming 55% of companies in the drug manufacturers industry. Its financial strength is rated 3 out
The Vanguard Health Care Fund (Trades, Portfolio), which invests at least 80% of its assets in stocks of companies principally related to the health care industry, bought shares of the following stocks in both the second and third quarters.
Anthem Inc. (ANTM)
The fund increased its position by 17.36% in the second quarter and then raised it by 4.17% in the third quarter. The stock has a weight of 2.45% in the portfolio.
The American managed-care organization has a market cap of $68.90 billion. Its revenue of $100.17 billion has grown
Mylan (MYL) continues to face multiple headwinds including a challenging regulatory environment, pricing pressure on generic drugs in the U.S., and slower than expected regulatory approval of new products. We used the recent merger announcement between Mylan and the Upjohn division of Pfizer as an opportunity to trim into strength.
From [url=https://www.gurufocus.com/StockBuy.php?GuruName=Steven+Romick]Steven Romick[/url] ([url=https://www.gurufocus.com/StockBuy.php?GuruName=Steven+Romick]Trades[/url], [url=https://www.gurufocus.com/holdings.php?GuruName=Steven+Romick]Portfolio[/url])'s FPA Crescent Fund 3rd-quarter 2019 commentary.
If it’s true that busy hands are happy hands, then the management team at Pfizer Inc. (PFE) must be ecstatic.
In just the past few months, the company has:
- Agreed to spin off Upjohn, the manufacturer of Pfizer’s drugs that no longer enjoy patent protection, and combine the unit with Mylan (MYL), a U.K-based generic company.
- Acquired Array to boost its biotech pipeline in a deal valued at about $11.4 billion.
- Announced it is investing $500 million in a gene therapy manufacturing plant in North Carolina to complement money it has already socked into other facilities aimed at producing
The fund established a new position in Pfizer Inc. (PFE), buying 22.29 million shares. The trade had an impact of 2.22% on the portfolio.
The pharmaceutical company has a market cap of $212.67 billion and an enterprise value of $246.56 billion.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. The return on equity of 18.97% and return on assets of 7.79% are outperforming 51% of
Now that Pfizer (PFE)'s Upjohn and Mylan (MYL) are combining in a new spinoff, it looks like Teva (TEVA) could be next. Judging by price movements in Teva since Pfizer made its move, some traders may be anticipating this. The stock is up nearly 7% since the deal was announced.
But buying Teva on the assumption of it being acquired is more risky than it looks, even at these levels. Here’s why.
First, it can hardly be said that Pfizer and Mylan joining forces is good for Teva in any fundamental sense. The new company will have a healthier balance
Dow stocks was higher on Monday, with 3M Co. (MMM) and Johnson & Johnson (JNJ) pulling the index up. The Dow Jones Industrial Average gained 0.15% to 27,234, the S&P 500 index fell 0.16% to 3,020 and the NasdaqComposite Index dipped 0.51% to 8,288.
Shares of Anadarko Petroleum Corp. (APC) slid more than 0.5% after the company announced second-quarter results. It posted earnings of 51 cents per share on $3.44 billion in revenue, reflecting 4.6% growth
Drugmaker Pfizer Inc. (PFE) announced on Monday it is combining its off-patent drug business, which is called Upjohn, with Pittsburgh-based generic pharmaceutical giant Mylan NV (MYL) in an all-stock deal, creating a new company.
According to the terms of the agreement, each share of Mylan will be converted into one share of the new company, which will be domiciled in the U.S. and renamed and rebranded upon closing. The deal will be structured as a reverse Morris trust, in which Upjohn will be divested from the New York-based company and then combined with Mylan.
Once the deal closes, Pfizer
Mylan NV (MYL) might be a good case study for MBA candidates on how not to run a company.
Students would probably find many of the company’s moves comical, but investors aren't laughing. Mylan is one of the worst-performing Dow stocks this year. And since April 2015, shares of the Pittsburgh-based generic pharmaceutical giant have lost 75% of their value. That was about the time Mylan rejected Teva Pharmaceutical’s (TEVA) offer to buy the company for $82 a share.
Wouldn’t Mylan love to have a do-over? At the time, Executive Chairman Robert Coury summarily dismissed the Teva offer because he
Drugmaker Mylan NV (MYL) reported disheartening first-quarter results before the opening bell on Tuesday, sending shares lower in premarket trading.
The British pharmaceutical company, which also has offices in Pennsylvania, posted a $25 million net loss, or 5 cents per share, for the quarter. Adjusted earnings of 82 cents per share beat Refinitiv’s estimates of 79 cents, but were down 15% from a year ago.
Total revenue declined 7% from the prior-year quarter to $2.5 billion, missing expectations of $2.69 billion. The company attributed the mediocre performance to manufacturing problems and restructuring efforts at its Morgantown plant in West
Bristol-Myers Squibb Company (BMY), Annaly Capital Management Inc. (NLY), Newell Brands Inc. (NWL) and Mylan NV (MYL) have declined to their three-year lows.
Bristol-Myers Squibb Company (BMY) declined to $45.57
The prices of CVS Health Corp (CVS) shares have declined to $52.81, which is only 2.0% above the 3-year low of $51.77.
Bristol-Myers Squibb Company is an American international pharmaceutical company that manufactures prescription pharmaceuticals in various therapeutic areas including cancer, cardiovascular diseases, diabetes, hepatitis, and HIV.
Bristol-Myers Squibb Company has a market cap of $74.4 billion; its shares were traded around $45.57 with a P/E ratio of 15.02 and
U.S. stocks were mostly lower Thursday on concerns regarding the U.S.-China trade deal, with a meeting between President Donald Trump and Chinese President Xi Jinping pushed back to April. The Dow Jones Industrial Average advanced 0.03% to 25,710, the S&P 500 Index fell 0.06% to 2,809 and the Nasdaq Composite Index slid 0.08% to 7,637.
Shares of MongoDB Inc. (MDB) jumped almost 27% after the company announced fourth-quarter results Thursday evening. Revenue grew 70.8% from the prior-year quarter to $85.5 million, beating expectations by $11.48 million. The company reported a loss of 17 cents per share, topping estimates by 21
It has been a rough ride for investors of pharmaceutical giant Mylan NV (MYL). Shares are down 11% off the back of a disappointing fourth-quarter earnings report that came out after the market closed on Tuesday.
The drop itself follows a weak year-over-year performance - since March 2018, the stock is down around 34%. Currently trading at $27 per share and with a market cap of $13.9 billion, the company has certainly seen better days. Is this an opportunity to buy a solid biotech that just happens to be down on its luck, or should investors stay away?
While gurus hold positions in these companies, their stock prices and returns continue to fall. The following are the worst-performing stocks over the last three months with a long-term presence in more than four gurus’ portfolios.
Shares of Mylan NV (MYL) declined 20.6% over the last six months. The stock is held by 11 gurus.
The pharmaceutical company has a $15 billion market cap. The stock is trading with a price-earnings ratio of 29.40. The share price of $28.77 is 35.64% below its 52-week high and 10.51% above its 52-week low.
Over the last
Typically, fund managers wait to disclose buys and sales until the SEC-required date of 45 days after the end of the quarter, but sometimes they let investors know some of their dealings through interviews or letters. Einhorn made public the information during his third-quarter conference call to discuss another dismal quarter in which his fund slid a further 8.4%, with a loss of 21.4% for the year through October.
AbbVie Inc. (ABBV) announced on Oct. 11 that it has reached an agreement with Sandoz, a unit of Novartis AG (NVS), for the settlement of the patent infringement litigation connected with its top-selling drug, Humira.
The licensing agreement is non-exclusive and allows Sandoz to sell its Humira biosimilar in the U.S. starting on Sept. 30, 2023. AbbVie will receive undisclosed royalties on net sales from Sandoz.
Sandoz's U.S. license will not be accelerated by the entry of Amgen Inc. (AMGN), Samsung Bioepis (BIIB) and Mylan NV (MYL). The global resolution with Samsung Bioepis will be effective in the U.S. on
[url=http://www.gurufocus.com/StockBuy.php?GuruName=David+Einhorn]David Einhorn[/url] ([url=http://www.gurufocus.com/StockBuy.php?GuruName=David+Einhorn]Trades[/url], [url=http://www.gurufocus.com/holdings.php?GuruName=David+Einhorn]Portfolio[/url])’s year has gone awry, with his hedge fund Greenlight Capital reporting mounting losses for the month of September that put him on course for his firm’s worst annual performance.
Einhorn’s investment returns slumped 1.8% for the month for a 22.3% loss for the year. Bloomberg has reported a steeper loss in his main fund, at 26.1%, citing an investor update. Meanwhile, the S&P 500 Index gained 8.17% for the same period.
The losses stem from both his long and short positions. Einhorn, a value investor, concentrated more than half his public long portfolio in the second
Amgen Inc. (AMGN) has not been affected by the decision of the European Commission to approve Coherus BioSciences’ (CHRS) UDENYCA for commercialization in Europe. The stock ended only slightly lower at $206.46 per share on Tuesday compared to the previous close.
UDENYCA, one of the first pegfilgrastim products to gain the European marketing authorization, is a biosimilar of Amgen's Neulasta.
Coherus Biosciences also submitted the U.S. Food and Drug Administration with a marketing application for UDENYCA. The U.S. agency is currently reviewing the application. The action date is scheduled for Nov. 3.
The U.S. FDA also approved Mylan (MYL)'s Fulphila
Teva Pharmaceuticals (TEVA) is not a company I would typically consider investing in. It was a mere three years ago that it hit an all-time high of $70, only to sink to $11 in November 2017. The decline in stock price correlated with the spike in debt and to many, the glory days of Teva had officially come to an end.
This decline makes sense. Teva specializes in manufacturing generic pharmaceuticals. In other words, once a drug comes off patent, it is generally a race to the bottom to manufacture drugs and ensure they
Stock market indexes were trading in positive territory on Friday after Federal Reserve Chairman Jerome Powell's speech, in which he said the U.S. economy will remain strong. The central bank is expected to increase interest rates in September.
Shares of Autodesk Inc. (ADSK) jumped more than 10% on Friday morning after the company posted second-quarter results on Thursday evening. The company recorded earnings per share of 19 cents on $612 million in revenue, growing 22% year over year. It beat earnings estimates by 3 cents and revenue expectations by $11.66 million.
The company's annualized recurring revenue from subscription plans increased